Boston Scientific Corporation (NYSE:BSX) is one of Goldman Sachs’ top healthcare stock picks. On July 7, Boston Scientific (NYSE:BSX) saw its shares rise as TD Cowen reaffirmed its Buy rating and $115 price target following FDA approval to expand the use of its Farapulse system for treating persistent atrial fibrillation (AFib).
Image: Courtesy of Boston Scientific
Previously approved for paroxysmal AFib, the system showed strong safety and efficacy results in clinical trials, with no strokes and over 85% of patients free from arrhythmia recurrence after one year.
The company sees significant growth potential in persistent AFib, which accounts for 25–50% of cases and anticipates further regulatory approvals in Europe, Japan, and China. Boston Scientific is also advancing new clinical research with the ReMatch trial, highlighting its continued innovation in cardiac care solutions.
Boston Scientific Corporation (NYSE:BSX) is a medical technology company that develops, manufactures, and markets medical devices. Its products are used in various interventional medical specialties to improve patient outcomes and address unmet needs.
While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 11 Best Green Energy Penny Stocks to Buy Right Now and 10 Most Popular AI Penny Stocks to Buy According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.